ITI-007是Intra-Cellular Therapies有限公司開發(fā)的一種非典型抗精神分裂癥藥物。到目前為止,在已完成的臨床前和臨床試驗(yàn)中,該藥表現(xiàn)出了結(jié)合強(qiáng)效5-HT_2A受體拮抗劑、多巴胺受體磷酸化調(diào)節(jié)劑(DPPM)、谷氨酸調(diào)節(jié)劑以及5-羥色胺再攝取抑制劑于一身的特點(diǎn),可用于治療急性及殘留型精神分裂癥,為上述癥狀的單一結(jié)構(gòu)候選藥物。ITI-007同時(shí)還具有改善睡眠質(zhì)量的效果,并能減少精神分裂癥的陰性癥狀,對(duì)抑郁、焦慮以及與受損的社會(huì)功能相關(guān)的其他癥狀也有一定效果。與許多其他抗精神病藥物如利培酮不同,ITI-007不會(huì)導(dǎo)致糖尿病和心血管疾病風(fēng)險(xiǎn)的增加,因此與許多現(xiàn)有抗精神分裂癥藥物相比,后者在長期的安全性和耐受性方面可能會(huì)有明顯改善。

ITI-007 is an atypical antipsychotic drug which is currently under development by Intra-Cellular Therapies Co. Ltd. In pre-clinical and clinical trials to date, ITI-007 combines potent serotonin 5-HT_2A receptor antagonism, dopamine receptor phosphoprotein modulation (DPPM), glutamatergic modulation, and serotonin reuptake inhibition into a single drug candidate for the treatment of acute and residual schizophrenia. ITI-007 has demonstrated significantly improvements in quality of sleep, and reducing the negative symptoms of schizophrenia, and has certain effects in treatment of depression, anxiety, and other symptoms associated with impaired social function. Different from many other antipsychotics such as risperidone, ITI-007 may not cause an increase in the risk of diabetes or cardiovascular disease. Therefore ITI-007 may prove to be a significant improvement relative to many existing antipsychotic drugs in terms of long-term safety and tolerability.